VivoSim Labs, INC. (VIVS): Nasdaq/NYSE listing notice — Organovo receives Nasdaq delisting notice for bid price non-compliance; intends to appeal with reverse split plan

VivoSim Labs, INC.

Nasdaq notified Organovo on Jan 16, 2025 that it failed to regain compliance with $1 minimum bid price rule.
Company is not eligible for a second 180-day compliance period on The Nasdaq Capital Market.
Organovo intends to timely request a hearing, which will automatically stay any delisting pending a decision.
Hearing panel may grant an extension up to July 15, 2025; company plans to propose a reverse stock split.
Common stock continues to trade on Nasdaq under symbol ONVO pending the hearing outcome.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

VivoSim Labs, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

January 16, 2025, the Staff provided a notice to the Company (the “Nasdaq Notice”) that the Company had not regained compliance with Rule 5550(a)(2) and is not eligible for a second 180 calendar day compliance period as

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

VivoSim Labs, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

January 16, 2025, the Staff provided a notice to the Company (the “Nasdaq Notice”) that the Company had not regained compliance with Rule 5550(a)(2) and is not eligible for a second 180 calendar day compliance period as the Company does not comply with the requirements for initial listing on The Nasdaq Capital Market. The Nasdaq Notice further indicated that, unless the Company timely requests a hearing before a Hearings Panel (the “Panel”), the Company’s common stock would be subject to delisting. As a result, the Company intends to timely request a hearing. The hearing request will automatic

View on SEC.gov

Browse all listing & compliance notices →

VivoSim Labs, INC. filing history →

Source: SEC EDGAR

accession 0000950170-25-006819

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.